These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 7471120)

  • 21. Hematologic and histopathologic evaluation of N-(phosphonacetyl)-L-aspartate (PALA) in mice.
    Harrison SD; Giles HD; Denine EP
    Cancer Chemother Pharmacol; 1979; 2(3):183-7. PubMed ID: 455573
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II study of PALA and AMSA in advanced renal cell carcinoma.
    Earhart RH; Elson PJ; Rosenthal SN; Hahn RG; Slayton RE
    Am J Clin Oncol; 1983 Oct; 6(5):555-60. PubMed ID: 6688498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.
    Casper ES; Michaelson RA; Kemeny N; Martin DS; Young CW
    Cancer Treat Rep; 1984 Mar; 68(3):539-41. PubMed ID: 6704982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.
    Muss HB; Bundy B; DiSaia PJ; Stehman FB; Beecham J
    Am J Clin Oncol; 1984 Dec; 7(6):741-4. PubMed ID: 6528869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of PALA in hypernephroma and urinary bladder cancer.
    Natale RB; Yagoda A; Kelsen DP; Gralla RJ; Watson RC
    Cancer Treat Rep; 1982 Dec; 66(12):2091-2. PubMed ID: 7139651
    [No Abstract]   [Full Text] [Related]  

  • 26. PALA in advanced breast cancer. A phase II pilot study by the ECOG.
    Taylor SG; Davis TE; Falkson G; Keller AM
    Am J Clin Oncol; 1982 Dec; 5(6):627-9. PubMed ID: 7165004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II evaluation of PALA in patients with metastatic lung cancer.
    Creagan ET; Eagan RT; Fleming TR; Frytak S; Nichols WC; Ingle JN; Kvols LK
    Cancer Treat Rep; 1981; 65(3-4):356-7. PubMed ID: 7237459
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase II study of PALA in advanced large bowel carcinoma.
    Rubin J; Purvis J; Britell JC; Hahn RG; Moertel CG; Schutt AJ
    Cancer Treat Rep; 1981; 65(3-4):335-6. PubMed ID: 6453645
    [No Abstract]   [Full Text] [Related]  

  • 29. Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. I. Embryolethal, teratogenic, and cytogenetic effects.
    Sieber SM; Botkin CC; Soong P; Lee EC; Whang-Peng J
    Teratology; 1980 Dec; 22(3):311-9. PubMed ID: 7233336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of chlorozotocin.
    Gralla RJ; Tan CT; Young CW
    Cancer Treat Rep; 1979 Jan; 63(1):17-20. PubMed ID: 154363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral leukocytes as indicators of the enzymatic effects of N-(phosphonacetyl)-L-aspartic acid (PALA) on human L-aspartate transcarbamoylase (ATCase) activity.
    Kensler TW; Erlichman C; Jayaram HN; Tyagi AK; Ardalan B; Cooney DA
    Cancer Treat Rep; 1980; 64(8-9):967-73. PubMed ID: 7448831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of PALA in lymphoma: an Eastern Cooperative Oncology Group study.
    Muggia FM; Tsiatis AA; O'Connell MJ; Glick JH; Opfell RW; Coren A
    Cancer Treat Rep; 1984 Mar; 68(3):551-3. PubMed ID: 6231103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II evaluation of PALA in patients with advanced head and neck cancer.
    Creagan ET; Nichols WC; O'Fallon JR
    Cancer Treat Rep; 1981; 65(9-10):827-9. PubMed ID: 7273014
    [No Abstract]   [Full Text] [Related]  

  • 37. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
    Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
    Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
    Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
    Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
    Marshall JL; Wellstein A; Rae J; DeLap RJ; Phipps K; Hanfelt J; Yunmbam MK; Sun JX; Duchin KL; Hawkins MJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2347-54. PubMed ID: 9815633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.